VYNDAQEL
Identification of Vyndaqel
| No description |
Google image searchProduct monograph
Active ingredient
tafamidis meglumine, 20 MG
DIN: 02495732
Dosage form(s): CAPSULE
Route(s) of administration: ORAL
Schedule: Prescription
Company: PFIZER CANADA ULC
Date: 07-APR-2020
ATC:
- N07 — OTHER NERVOUS SYSTEM DRUGS (ATC, ATC/DDD, )
- N07X — OTHER NERVOUS SYSTEM DRUGS (ATC, ATC/DDD)
- N07XX — Other nervous system drugs (ATC, ATC/DDD)
- N07XX08 — TAFAMIDIS (ATC/DDD)
Pharmaceutical standard: MFR
